Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines

Pharmacol Ther. 2023 Sep:249:108485. doi: 10.1016/j.pharmthera.2023.108485. Epub 2023 Jul 3.

Abstract

Autophagy is a conserved process in which the cytosolic materials are degraded and eventually recycled for cellular metabolism to maintain homeostasis. The dichotomous role of autophagy in pathogenesis is complicated. Accumulating reports have suggested that cytoprotective autophagy is responsible for tumor growth and progression. Autophagy inhibitors, such as chloroquine (CQ) and hydroxychloroquine (HCQ), are promising for treating malignancies or overcoming drug resistance in chemotherapy. With the rapid development of nanotechnology, nanomaterials also show autophagy-inhibitory effects or are reported as the carriers delivering autophagy inhibitors. In this review, we summarize the small-molecule compounds and nanomaterials inhibiting autophagic flux as well as the mechanisms involved. The nanocarrier-based drug delivery systems for autophagy inhibitors and their distinct advantages are also described. The progress of autophagy inhibitors for clinical applications is finally introduced, and their future perspectives are discussed.

Keywords: Autophagy inhibitors; Cancer; Chemosensitization; Chemotherapy; Nanomaterials; Nanomedicines.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy* / drug effects
  • Autophagy-Related Protein-1 Homolog / antagonists & inhibitors
  • Clinical Trials as Topic
  • Drug Resistance, Neoplasm / drug effects
  • Humans
  • Nanoparticle Drug Delivery System
  • Nanostructures* / therapeutic use
  • Neoplasms* / drug therapy
  • Small Molecule Libraries* / pharmacology
  • Small Molecule Libraries* / therapeutic use

Substances

  • Small Molecule Libraries
  • Autophagy-Related Protein-1 Homolog
  • Nanoparticle Drug Delivery System